Xenon Pharmaceuticals Inc. annual report, FY2020

Xenon Pharmaceuticals Inc. — FY2020 Form 10-K

Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 report. Unless indicated otherwise, amounts are U.S. dollars.

Business context

Xenon is a clinical-stage biopharmaceutical company developing therapies for neurological disorders, particularly epilepsy. It had no marketed products or product-sale revenue in 2020; reported revenue came from collaborations and licensing.

Proprietary pipeline: XEN1101 was in Phase 2b for focal epilepsy; XEN496 entered Phase 3 for pediatric KCNQ2-DEE; and XEN007 was in a physician-led Phase 2 study for treatment-resistant childhood absence epilepsy.
Partnered programs: Neurocrine Biosciences is developing NBI-921352 (formerly XEN901) for epilepsy. Flexion is developing FX301 (formerly XEN402) for post-operative pain. Genentech holds rights under a Nav1.7 collaboration.

Financial performance and liquidity

Metric	FY2020	FY2019
Revenue	$32.2 million	$6.8 million
Research and development expense	$50.5 million	$38.8 million
General and administrative expense	$12.9 million	$10.8 million
Operating loss	$31.3 million	$42.8 million
Net loss	$28.8 million	$41.6 million
Net loss per common share, basic and diluted	$0.81	$1.54
Cash used in operating activities	$48.1 million	$4.7 million
Cash and marketable securities at year-end	$177.0 million	$141.4 million

Revenue increased $25.3 million, primarily from recognition of Neurocrine collaboration consideration and reimbursement for research and development services. Neurocrine accounted for 100% of 2020 revenue.
Operating expenses rose $13.8 million, led by higher spending on XEN1101 and XEN496. The lower net loss reflected increased collaboration revenue and other income, despite increased operating expenses.
Operating cash use rose substantially from 2019, when upfront collaboration receipts provided a significant offset. Investing activities used $16.8 million; financing activities provided $85.8 million, primarily from share issuances.
Xenon repaid its Silicon Valley Bank term loan in May 2020. No term loan remained at year-end; the early repayment resulted in a one-time loss of approximately $1.0 million, including repayment fees.
Management said available cash and marketable securities were expected to fund operating and capital requirements for at least 12 months from the filing. The company nevertheless expects continued operating losses and anticipates needing additional funding over time.
No product gross margin was reported because Xenon had no product sales. Revenue and collaboration milestones are variable and are not a recurring product-sales base.

Material changes versus FY2019

Revenue rose from $6.8 million to $32.2 million, largely reflecting the timing of recognition of the Neurocrine upfront transaction price. In 2019, revenue also included Flexion’s upfront and milestone payments.
R&D expense increased 30% to $50.5 million. XEN1101 expense rose to $23.7 million and XEN496 to $12.3 million; XEN901-related expense fell as Neurocrine assumed development costs under the collaboration.
Net loss narrowed to $28.8 million from $41.6 million, while operating cash use increased to $48.1 million from $4.7 million.
Common shares outstanding increased to 35.0 million at year-end from 28.1 million, reflecting financing activity and other issuances.

Outlook, commentary and key risks

XEN1101: Management expected X-TOLE patient randomization in the first half of 2021 and topline Phase 2b data in the third quarter of 2021, dependent on enrollment. COVID-19 had slowed enrollment. A Phase 2 proof-of-concept study in major depressive disorder and anhedonia was also expected to start in 2021.
XEN496: The Phase 3 EPIK study was initiated in approximately 40 pediatric patients. Management emphasized that efficacy and safety remain unproven and that the FDA’s view that one small pivotal study may suffice is conditional.
Partner milestones: Neurocrine expected to begin a Phase 2 SCN8A-DEE study in adolescents in the third quarter of 2021, with younger children dependent on further FDA review. Flexion’s FX301 IND was cleared in February 2021, triggering a $1.0 million milestone due to Xenon; this is a post-year-end event.
Funding and dilution: Xenon expects significant expenses and operating losses for the foreseeable future. Additional financing may be required and could dilute shareholders or require granting rights to programs. The company reported $10.7 million of net proceeds from its August 2020 at-the-market program through March 1, 2021.
Other risks: Clinical outcomes, patient recruitment, regulatory approval, third-party manufacturing and collaborator execution are uncertain. The filing identifies COVID-19-related trial and operational disruption, foreign-exchange exposure (without current hedging), and reliance on Neurocrine for development of NBI-921352 as notable risks.
Contingency: A Medpace clinical-services agreement had an unsatisfied $3.7 million commitment at year-end. Xenon intended to use Medpace for appropriate future work; otherwise, it may satisfy the obligation by paying half the unsatisfied amount.

Important facts for investors to verify

Whether X-TOLE enrollment and its expected 2021 topline readout occurred on schedule, and the clinical results and safety profile.
Progress, enrollment and regulatory requirements for the EPIK Phase 3 study, including whether its data can support approval.
Neurocrine’s progress and the amended milestone conditions for NBI-921352, including the timing and form of any milestone consideration.
Current cash and marketable securities, quarterly operating cash use, remaining ATM capacity and expected financing needs.
The concentration and timing of collaboration revenue, since 2020 revenue depended entirely on Neurocrine and included recognition of previously received consideration.
Potential dilution from share offerings, outstanding options and convertible preferred shares; and any changes in debt, collaboration commitments or the Medpace obligation.